UBS Boosted PT on Jazz Pharmaceuticals (JAZZ) to $67

February 27, 2013 12:52 PM

UBS raised its price target on Buy-rated Jazz Pharmaceuticals (NASDAQ: JAZZ) from $64 to $67 following Q4 beat and outlook.

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found